During a 12-wk drug monitoring study,the efficacy and safety of aRhodiolarosea extractgiven in combination with vitamins and minerals (vigodana®) weretested in 120 adults (83 women and 37 men, ages 50–89 y) with physical andcognitive deficiencies. Two different dosage regimens were chosen. One groupof 60 patients (group 1) took 2 capsules orally in the morning after breakfast,and the other group (group 2) took 1 capsule after breakfast and 1 after lunch.Three medical examinations were perf

Choline alfoscerate(α-GPC;alpha GPC;L-alpha glycerylphosphorylcholine;CAS No.:28319-77-9)is common choline compound and acetycholine precursor in the brain, which hasbeen shown to be effective in the treatment of Alzheimer’s disease and dementia. α-GPC has been shown toenhance memory and cognitive function in stroke and Alzheimer’s patients but currently remains untested inpatients suffering fromepilepsy. This study aimed to evaluate whether α-GPC treatment after seizure canameliorate seizu

Rhodiola roseais a popular plant in traditional medical systems in Eastern Europe andAsia with a reputation for stimulating the nervous system, decreasing depression,enhancing work performance, eliminating fatigue, and preventing high altitude sickness.Rhodiola rosea has been categorized as an adaptogen by Russian researchers due toits observed ability to increase resistance to a variety of chemical, biological, and physicalstressors. Its claimed benefits include antidepressant, anticancer, card

Background:Rhodiola rosea(R. rosea) is a botanical adaptogen with putative anti-stress and antidepressant properties. Evidence-based data supporting the effectiveness of R. rosea for depression in adults islimited, and therefore a comprehensive review of available animal and human studies suggesting a putative antidepressant action is warranted.Purpose:A review of the literature was undertaken to ascertain studies of possible antidepressant mechanisms of action and studies of the safety and effe

β-Nicotinamide mononucleotide(short name:NMNCAS No.:1094-61-7)is an inherent metabolite of the human body, which can be directly converted into the keycoenzymeNAD+(NICOTINAMIDE ADENINE DINUCLEOTIDE; NAD+; β-NAD, CAS No.:53-84-9)Because NAD+ is an indispensable substance for nearly half of the human body's metabolic activities, but it declines rapidly with age. Therefore, taking NMN can increase theNAD+level, so that the energy level and gene repair ability of the capsule can be restored to

As we all know, whether in developed or developing countries, the incidence and mortality ofacute kidney injury(AKI) are increasing year by year. At present,renal replacement therapy(RRT) is one of the effective methods for the treatment ofAKI, and it is up to the clinician to make a decision when to carry outRRT. However, the emergence ofNicotinamide Mononucleotide(NMN)has brought new ideas for the treatment of this disease.China's top scientific research institution Peking University has p

In the past 3-4 years, Science, the most prestigious academic journal in the world, has continuously published experiments on the repairing effect ofNicotinamide Mononucleotide（NMNCAS No. :1094-61-7）on the human body. It has repeatedly proved thatsupplementation of NMNcan effectively increase and restore the level of coenzyme I in the body, greatly delay aging and prevent Alzheimer's disease, etc. A neuron degenerative disease, and thus fundamentally regulate and improve various symptoms o

Diabetic nephropathyis one of the most common chronic complications of diabetes, and its incidence is also on the rise. It has become the second cause of end-stage renal disease, second only to various glomerulonephritis. Because of its complex metabolic disorders, once it develops into end-stage renal disease, it is often more difficult than the treatment of other renal diseases. Therefore, timely prevention and treatment is of great significance to delaying diabetic nephropathy.The study found